NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. - Wikidata - awgldk - TriplyDB

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

http://www.wikidata.org/entity/Q43875846

about

Hepatic steatosis: a benign disease or a silent killer Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis Weight reduction for non-alcoholic fatty liver disease Weight reduction for non-alcoholic fatty liver disease Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma From the stomach to other organs: Helicobacter pylori and the liver Steatosis and hepatitis C Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease Signal transductions and nonalcoholic fatty liver: a mini-review Role of receptor for advanced glycation end products (RAGE) in liver disease Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats The role of air pollutants in initiating liver disease What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome.Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.Advanced MRI methods for assessment of chronic liver disease Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD).Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study.Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps.Fat and water magnetic resonance imaging.Metformin in nonalcoholic steatohepatitis: a randomized controlled trial Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease.Biphasic response of mitochondrial biogenesis to oxidative stress in visceral fat of diet-induced obesity mice.Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance.Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.Pathologic Impact of Insulin Resistance and Sensitivity on the Severity of Liver Histopathology in Pediatric Non-Alcoholic Steatohepatitis.Combined Effect of Initial and Longitudinal Increases in γ-Glutamyltransferase on Incident Metabolic Syndrome: ARIRANG Study.The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study.Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma

P2860

Q22305506-EEE49DA2-AAB3-4A82-8708-9D978F1730BA Q24197984-B36D2414-5DBB-40CF-80E4-B652EE41C790 Q24235200-7BDA032D-DF17-4865-BF58-81821AE799A5 Q24236500-5F674EC7-9F34-47E1-8FEE-2C9B5B3F30B8 Q24243033-DD6E1190-DAB6-48C8-B395-5669AFA607A5 Q24243125-B8F87973-1E6E-4623-B576-5470D1C61821 Q24246447-FE11B25B-EDF4-45F4-8E5B-2689AFDE19E6 Q24629354-79FA9A2A-176E-431E-A18D-64DAD293C8DF Q26748608-5641323E-0EA2-4278-9E12-77015A503ED3 Q26781477-37D84354-ED8F-44F0-97C8-EB1230BE4C75 Q26795532-429F91F2-936D-42D2-A603-AB2003D08045 Q26798101-29E599D7-2D9D-434D-8A70-195709CCDB17 Q26827169-024AE6DD-1570-4544-9691-DEB946D2D47C Q26828765-603279F6-AAAF-40BD-8C50-C2CACA5B66DA Q26852498-E9D2E497-3491-4953-91E2-42254F72A835 Q26991757-82ADDC53-945B-4D41-95B4-73D40F3F86D5 Q27010462-DA093BCC-A0A5-4E30-83A3-DB17122301DC Q28286911-FA2E229E-4200-4769-B036-B02247BA9B1B Q28397537-E0597CF3-2755-4C6E-ADF1-27FA5EDBB528 Q28541716-614B751D-0D95-4A1D-90CB-EEE60DED448A Q28655280-A3EA6A6B-1977-494B-A2D6-1A2836372370 Q30361645-4DBF3A10-1EC6-4D11-8FF2-5A6A1703F688 Q30431218-EA03E80E-D535-4871-9696-4E2260E59694 Q30443852-FA37A5AE-2660-4FA4-A6B2-E215D0150D19 Q30464608-647732C1-392A-4B0E-ACDD-680A5FDEE60A Q30478601-A09E750B-A8CB-48A8-B7A6-2A73564B76DF Q33202380-EA8899A7-8744-4078-A3FE-5C6FE36F62F1 Q33347569-8D195957-8524-4399-ADAB-03D1C75A1076 Q33410004-002B5F5B-6A7E-4CDC-BEBD-8B1FA9BFFC86 Q33516103-D1C973D2-C295-4FC5-BAF6-D05BDE18E5C3 Q33520271-AB7C07AD-09DC-466A-AD18-42A6E36D90C4 Q33597395-2E3CC477-CA5E-4D51-8802-64686A5BB758 Q33607793-88986745-6C35-412D-985F-EF9918273B32 Q33630100-682C74A4-6FE1-43BE-A910-56CC98DDFFE2 Q33642230-47E6A1EF-6F19-4132-BDC3-DEA5FFF88492 Q33724815-6A827B16-25DC-4F11-BEB2-DA4A7FD38F6F Q33734988-41AAADFF-ED88-42BD-90A2-7628E883E82B Q33734994-4F3EAFC6-4151-49F8-9C4C-678D41E625FF Q33757419-2A7CE973-54FA-4971-8597-69F08C108D4D Q33761751-F0E314C8-B396-4C38-9759-6F1313490B08

P2860

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.

http://www.wikidata.org/entity/Q43875846

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@en

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@nl

type

label

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@en

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@nl

prefLabel

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@en

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@nl

P1433

Q43875846-D4954F00-965E-4B7A-9DB3-7F45AB72B4B7

P1476

Q43875846-54BF0346-5589-4A5A-BCBD-BDF3829E7A0A

P2093

Q43875846-01C229E8-0C2E-4CC2-9AB4-CA9397B6022D

Q43875846-1029EDBE-183B-44BF-B7B2-3DE43B4A44FC

Q43875846-2F99FF7A-838E-402A-BDBA-96C6785A0881

Q43875846-3642BB6D-08E0-49AA-B1B5-699B63875057

Q43875846-3C63476E-68B4-4818-96BC-ADF3BD0E3181

Q43875846-3FE0A5C5-68A6-4552-87A2-876A6A65CB73

Q43875846-540FB31F-3C56-469E-BDE8-C4CB71FDF820

Q43875846-640C63B0-AD25-4F12-A406-801262EDA77D

Q43875846-75B5F1ED-C513-4DA2-A4B1-16058AF2AE1C

Q43875846-84133A97-6F33-4E0B-AB6E-0F5DC0FAB381

P304

Q43875846-9064AFA6-CFA7-49CE-846E-88F2B3122606

P31

Q43875846-B6408DD3-C7D0-457F-B7E8-223CB32AD09B

P356

Q43875846-71A8B55B-DA32-460A-B9D2-9DAC95EA62EA

P407

Q43875846-38210D62-FA11-441B-B88F-8584CA3CD5D8

P433

Q43875846-945C2F0E-EB24-471F-9FA3-AB037105FF1F

P478

Q43875846-5A9DD8D5-2D12-4EE1-8F64-BFEB0E8E772B

P50

Q43875846-294E9429-E972-4C3B-94E6-0E8AC4707FD4

P577

Q43875846-F6C04C40-6BE7-452D-BB35-FE81CC3B91B0

P698

Q43875846-C78E8757-DA56-4F23-95DA-5996864F4124

P921

Q43875846-2C0C22C6-6696-495D-BA5C-D4664825AC6E

P356

JHEP.2002.30692

P1433

P1476

NASH and insulin resistance: I ...... e insulin resistance syndrome.

@en

P2093

Caroline Fung

http://www.w3.org/2001/XMLSchema#string

Christopher Liddle

http://www.w3.org/2001/XMLSchema#string

Dev Samarasinghe

http://www.w3.org/2001/XMLSchema#string

Geoffrey C Farrell

http://www.w3.org/2001/XMLSchema#string

Jacob George

http://www.w3.org/2001/XMLSchema#string

Jane Holmes-Walker

http://www.w3.org/2001/XMLSchema#string

Jason M Hui

http://www.w3.org/2001/XMLSchema#string

Martin Weltman

http://www.w3.org/2001/XMLSchema#string

Rita Lin

http://www.w3.org/2001/XMLSchema#string

Rooshdiya Karim

http://www.w3.org/2001/XMLSchema#string

P304

373-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.30692

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Shivakumar Chitturi

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11826411

http://www.w3.org/2001/XMLSchema#string

P921